Multiple biopharmaceutical collaborations were reached during the China International Import Expo, involving various fields such as hepatitis B and women's health

During the 7th China International Import Expo, multiple collaborations in the biopharmaceutical industry were reached, involving various disease areas such as hepatitis B and chronic obstructive pulmonary disease (COPD). In particular, several collaborations support the goals set by the World Health Organization to eliminate hepatitis B by 2030 and China's goal to achieve the complete elimination of leprosy hazards by 2030. GlaxoSmithKline signed a strategic cooperation memorandum with the China Hepatitis Prevention and Control Foundation for a long-term management project for chronic hepatitis B, empowering patient management through digital intelligence, exploring innovative management models both inside and outside hospitals, and jointly supporting the achievement of the World Health Organization's goal to eliminate hepatitis B by 2030